24.04 USD
↘ 1.06 (4.22%)AT CLOSE (11:59 AM EDT)
Zymeworks Inc.
ZYMENASDAQ • USD
23.17
↘ 0.88 (3.64%)
POST MARKET (AS OF 07:35 PM EDT)
Post Market
AS OF 07:35 PM EDT
23.17
↘ 0.88 (3.64%)
Market: CLOSED
Open?$25.04
High?$25.12
Low?$24.02
Prev. Close?$25.10
Volume?464.8K
Avg. Volume?691.8K
VWAP?$24.43
Rel. Volume?0.67x
Bid / Ask
Bid?$16.05 × 200
Ask?$25.33 × 100
Spread?$9.28
Midpoint?$20.69
Valuation & Ratios
Market Cap?1.8B
Shares Out?73.0M
Float?46.0M
Float %?62.3%
P/E Ratio?N/A
P/B Ratio?10.81
EPS?-$1.40
Dividend?0.00%
Ex-Dividend?N/A
ZYME is currently priced at $24.04. Both sides of the analysis point lower: technicals flash "Sell" and fundamentals confirm with a "Sell" reading. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 2/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.
Technical & fundamental data as of Jun 5, 2026.
News
Profile
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Themes
Employees
264
Market Cap
1.8B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2017-04-28
Address
108 PATRIOT DRIVE, SUITE A
MIDDLETOWN, DE 19709
Phone: 302-274-8744
MIDDLETOWN, DE 19709
Phone: 302-274-8744
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?12
Z-Score?5
Momentum?3
Short Sent.?54
Piotroski F-Score?2/9Weak
Altman Z-Score?0.49Distress
Confidence?62%Moderate
Short InterestHigh
Short % of Float?9.73%Elevated
Short Interest?4.5M
Days to Cover?6.6
Free Float46.0M
Avg Daily Volume673.3K
Settlement Date2026-05-15
Financial Health
Current Ratio?10.82Strong
Quick Ratio?10.82Strong
Cash Ratio?6.85Strong
Debt/Equity?0.00Low
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score50/100
P/E?N/A▾
P/B?10.81HIGH▾
Peers100
S&P18
P/S?21.77HIGH▾
Peers100
S&P3
P/FCF?N/A▾
EV/EBITDA?-14.1CHEAP▾
S&P97
EV/Sales?18.76HIGH▾
Peers100
S&P3
Returns & Efficiency
ROE?-62.7%WEAK▾
S&P3
ROA?-21.5%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-77037000
Enterprise Value?$1.5B
Fundamentals ratios updated end of day